Intraoperative detection of IDH‐mutant glioma using fluorescence lifetime imaging. Issue 4 (23rd December 2022)

• Record Type: Journal Article
• Authors: Noble Anbunesan, Silvia; Alfonso‐Garcia, Alba; Zhou, Xiangnan; Bec, Julien; Lee, Han Sung; Jin, Lee‐Way; Bloch, Orin; Marcu, Laura
• Is Part Of: Journal of biophotonics. Volume 16:Issue 4(2023)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-12-23
• Subjects: astrocytoma -- fluorescence lifetime -- IDH‐mutant glioma -- imaging -- neurosurgery -- oligodendroglioma; Photonics -- Periodicals; Optical materials -- Periodicals; Optics -- Periodicals; Medical instruments and apparatus -- Periodicals; 621.3605
• DOI: 10.1002/jbio.202200291
• Languages: English
• ISSNs: 1864-063X

Abstract

Abstract: Identifying isocitrate dehydrogenase (IDH)‐mutation and glioma subtype during surgery instead of days later can aid in modifying tumor resection strategies for better survival outcomes. We report intraoperative identification of IDH‐mutant glioma ( N = 12 patients) with a clinically compatible fluorescence lifetime imaging (FLIm) device (excitation: 355 nm; emission spectral bands: 390/40 nm, 470/28 nm, 542/50 nm). The fluorescence‐derived parameters were analyzed to study the optical contrast between IDH‐mutant tumors and surrounding brain tissue. IDH‐mutant oligodendrogliomas exhibited shorter lifetimes (3.3 ± 0.1 ns) than IDH‐mutant astrocytomas (4.1 ± 0.1 ns). Both IDH‐mutant glioma subtypes had shorter lifetimes than white matter (4.6 ± 0.4 ns) but had comparable lifetimes to cortex. Lifetimes also increased with malignancy grade within IDH‐mutant oligodendrogliomas (grade 2: 2.96 ± 0.08 ns, grade 3: 3.4 ± 0.3 ns) but not within IDH‐mutant astrocytomas. The current results support the feasibility of FLIm as a surgical adjuvant for identifying IDH‐mutant glioma tissue. Abstract : Identifying the glioma subtype during surgery can aid in modifying resection strategies, as each glioma subtype responds differently to post‐surgical therapy. FLIm provides optical contrast between IDH‐mutant astrocytoma and IDH‐mutant oligodendroglioma, and between IDH‐mutant tumor and surrounding white matter. This study supports the feasibility of fluorescence lifetime imaging (FLIm) to identify IDH‐mutant glioma subtype intraoperatively.